On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

Sanofi  (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, ...

The North Bay Parry Sound District Health says a new preventive medication for Respiratory Syncytial Virus (RSV) for newborns ...

The North Bay Parry Sound District Health Unit announced the availability of a new preventive medication for Respiratory Syncytial Virus for newborns and eligible infants up to 24 months of age. The ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €112.00.

Olympic gold medalist gymnast Shawn Johnson East had respiratory syncytial virus-related experiences with all 3 of her ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi SA (SNY) reports a robust 16% sales increase, driven by Dupixent and vaccines, while navigating market challenges and ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...